The oral therapy tofacitinib citrate (Xeljanz) has gained a PBS listing for the treatment of moderate to severe rheumatoid arthritis. It is the first Janus kinase (JAK) inhibitor to be given the greenlight by the PBS and will be reimbursed from 1st October. At a recommended dosage of 5mg twice daily, Pfizer’s Xeljanz can be ...
First oral JAK gets PBS
4 Oct 2015